PMID- 15304005
OWN - NLM
STAT- MEDLINE
DCOM- 20050307
LR  - 20061115
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 64
IP  - 3
DP  - 2004 Sep
TI  - HLA class I serotypes and cytotoxic T-lymphocyte responses among human 
      immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in 
      combination with monomeric gp120 or oligomeric gp160 protein boosting.
PG  - 251-6
AB  - Antigen-induced cellular immunogenicity may vary between populations due to 
      differences in human leukocyte antigen (HLA) diversity and, hence, may play a 
      critical role in the protection afforded by vaccines. In the setting of two, 
      phase I/II human immunodeficiency virus-1 vaccine trials of a recombinant 
      canarypox prime, and boosting with either recombinant monomeric gp120 or 
      oligomeric gp160, we assessed the association between specific human leukocyte 
      antigen (HLA) class I serotypes and the presence of cytotoxic T-lymphocyte 
      response measured by 51Cr-release assay. HLA class I serotypes A11, A24, A33, 
      B46, and B75 were the most common, present in 10% or more of 245 individuals 
      studied. Forty of 187 (21.4%) Thai adults who received either ALVAC-HIV with 
      gp120 or oligomeric gp160 or ALVAC alone had a precursor cytolytic CD8 T-cell 
      response (pCTL). HLA-B44 was positively and significantly associated with a pCTL 
      response (odds ratio 7.6, 95% CI: 2.7-21.2), whereas B46 was negatively 
      associated but not robust when adjusted for multiple comparisons. Responses to 
      Env proteins accounted for the majority (nine of 11) of pCTL activity among those 
      persons with B44. This HLA class I serotype occurred in 9.4% of participants 
      overall (including the placebo group), less commonly than what is reported from 
      populations of European ancestry. These results strengthen the importance of 
      assessing HLA class I distributions in conjunction with studies of vaccines 
      designed to elicit cellular immunity in different populations.
FAU - Paris, R
AU  - Paris R
AD  - Department of Retrovirology, U.S. Army Medical Component, Armed Forces Research 
      Institute of Medical Sciences, Bangkok, Thailand. robert.paris@afrims.org
FAU - Bejrachandra, S
AU  - Bejrachandra S
FAU - Karnasuta, C
AU  - Karnasuta C
FAU - Chandanayingyong, D
AU  - Chandanayingyong D
FAU - Kunachiwa, W
AU  - Kunachiwa W
FAU - Leetrakool, N
AU  - Leetrakool N
FAU - Prakalapakorn, S
AU  - Prakalapakorn S
FAU - Thongcharoen, P
AU  - Thongcharoen P
FAU - Nittayaphan, S
AU  - Nittayaphan S
FAU - Pitisuttithum, P
AU  - Pitisuttithum P
FAU - Suriyanon, V
AU  - Suriyanon V
FAU - Gurunathan, S
AU  - Gurunathan S
FAU - McNeil, J G
AU  - McNeil JG
FAU - Brown, A E
AU  - Brown AE
FAU - Birx, D L
AU  - Birx DL
FAU - de Souza, M
AU  - de Souza M
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (ALVAC vaccine)
RN  - 0 (HIV Envelope Protein gp120)
RN  - 0 (HIV Envelope Protein gp160)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Adult
MH  - Female
MH  - HIV Envelope Protein gp120/immunology
MH  - HIV Envelope Protein gp160/immunology
MH  - HIV Infections/immunology/*prevention & control
MH  - HIV-1/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Male
MH  - T-Lymphocytes, Cytotoxic/*immunology/virology
MH  - Thailand
MH  - Viral Vaccines/*administration & dosage/immunology
EDAT- 2004/08/12 05:00
MHDA- 2005/03/08 09:00
CRDT- 2004/08/12 05:00
PHST- 2004/08/12 05:00 [pubmed]
PHST- 2005/03/08 09:00 [medline]
PHST- 2004/08/12 05:00 [entrez]
AID - TAN270 [pii]
AID - 10.1111/j.1399-0039.2004.00270.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2004 Sep;64(3):251-6. doi: 10.1111/j.1399-0039.2004.00270.x.